SECTOR NOTE · PUBLIC

AI-IRF Healthcare Sector Note

AI incident-response considerations for healthcare environments.

Publication content

ODA3 INSTITUTE — SECTOR APPLICATION NOTE

Healthcare

| 79 controls across 19 domainsApplying AI-IRF® v1.0 in hospitals, diagnostics, medical devices, and health data platforms — mapping controls to FDA SaMD guidance, HIPAA, EU AI Act medical device obligations, and CDSCO AI frameworks

1. Why AI Governance Certification Matters in Healthcare

Healthcare AI — diagnostic imaging analysis, clinical decision support, patient risk stratification, drug discovery acceleration, and administrative automation — is growing rapidly. The stakes are uniquely high: AI errors can directly harm patients, expose organisations to liability, and trigger regulatory action. Healthcare regulators in the US, EU, and India have all moved to establish AI-specific governance expectations, and the pace of regulatory development is accelerating.

AI IRF CERT® certification provides healthcare organisations with a structured, independently audited framework for AI governance that maps directly to FDA, EU AI Act, HIPAA, and emerging CDSCO requirements. For medical technology companies seeking market access in multiple jurisdictions, a single AI governance certification that speaks to multiple regulatory frameworks reduces compliance cost and time-to-market friction.

2. Regulatory Landscape

2.1 FDA — Software as a Medical Device (SaMD) Guidance

The FDA's regulatory framework for AI/ML-based Software as a Medical Device (SaMD) is established through the 2021 Action Plan for AI/ML-Based SaMD and subsequent guidance documents. Key elements applicable to AI governance:

Total Product Lifecycle (TPLC) approach: FDA expects ongoing monitoring of AI/ML SaMD performance throughout its lifecycle, not only at pre-market submission. Post-market surveillance plans must address AI-specific performance drift.

Predetermined Change Control Plan (PCCP): AI/ML SaMD that is designed to learn and change over time must submit a PCCP describing anticipated modifications, performance thresholds, and the criteria that would trigger regulatory re-submission.

Good Machine Learning Practice (GMLP): FDA has published guiding principles for GMLP, covering data management, model development, testing, deployment, and monitoring — all of which map to AI-IRF® v1.0 control domains.

De Novo and 510(k) submissions: AI components of medical devices are assessed for substantial equivalence and safety/effectiveness. Governance documentation produced under AI-IRF® v1.0 supports these submissions.

2.2 HIPAA — Health Insurance Portability and Accountability Act (US)

HIPAA's Privacy Rule and Security Rule apply to AI systems that process Protected Health Information (PHI). Relevant obligations:

Minimum necessary standard: AI models trained on PHI must be validated to use only the minimum data necessary for the intended purpose — maps to AI-IRF® v1.0 BOM-3 (data minimisation).

Access controls: AI systems accessing PHI require documented access control, audit logging, and transmission security — maps to ZTA-1 through MEX-1.

Business Associate Agreements (BAAs): where AI platforms or model training services are provided by third parties handling PHI, BAAs are required — maps to BOM-3 and BOM-3/REG-3.

Breach notification: AI-related data breaches (model inversion attacks, training data reconstruction) trigger HIPAA breach notification obligations — maps to SEV-RPT/MSR-3 (incident response).

2.3 EU AI Act — Medical Device and Healthcare AI

The EU AI Act classifies AI systems in the following healthcare categories as high-risk (Annex III): AI intended to be used as a safety component of medical devices covered by EU MDR (2017/745) and IVDR (2017/746); AI used in emergency despatch; and AI used in clinical trials for medicinal products. These systems must comply with Articles 9–15 (risk management, data governance, technical documentation, record-keeping, transparency, human oversight, accuracy and robustness).

AI that is itself a medical device (AI-as-SaMD) has a combined conformity assessment pathway covering both EU MDR/IVDR requirements and EU AI Act requirements. The notified body assessment under MDR/IVDR will increasingly look for AI governance evidence aligned with the EU AI Act framework — AI-IRF® v1.0 provides that evidence.

2.4 CDSCO — AI/ML Medical Device Guidance (India)

India's Central Drugs Standard Control Organisation (CDSCO) has issued draft guidance on AI/ML-based medical devices, requiring: validation against Indian patient populations (not only international datasets); bias assessment for Indian demographic groups; documentation of model training data provenance; and post-market surveillance plans for AI/ML devices. AI-IRF® v1.0's data governance and bias assessment controls (BOM-1–5, REG-4) directly address CDSCO's population-specific validation expectations.

3. AI-IRF® v1.0 Control Mapping — Healthcare Note: The following mapping covers the 13 original AI-IRF® v1.0 domains. The 6 normative extension domains (CSS-1–7, FL-1–4, MMD-1–3, QBS-1–3, HAL-1–3, PQC-1) from ODA3-ECO-011/013/014/015 are additionally applicable in sectors handling synthetic media, federated model training, AI-generated content, or quantum-sensitive data.

4. Sector-Specific Control Guidance

4.1 Diagnostic Imaging AI (Radiology, Pathology, Ophthalmology)

MLC-3 (validation methodology): diagnostic imaging AI must be validated on datasets representative of the target patient population. Single-institution datasets are insufficient — multi-site validation is expected by FDA and EU regulators. AI-IRF® v1.0 MLC-3 requires documented validation methodology including dataset diversity.

BOM-2 (bias assessment): imaging AI has well-documented performance disparities across skin tone (dermatology AI), sex (chest X-ray AI), and age (bone age AI). Bias assessment must test across these dimensions and document results.

REG-2 (explainability by risk tier): diagnostic AI must provide sufficient explainability for the reporting clinician to understand and challenge the AI output. Saliency maps, confidence scores, or comparable outputs are required — not just a binary positive/negative result.

APA-1 (human-in-the-loop): diagnostic AI must be positioned as decision support, not autonomous diagnosis. The workflow must ensure clinician review — APA-1 verifies this is implemented, not just stated in product labelling.

4.2 Clinical Decision Support (CDS) AI

SEV-CLS (AI incident register): CDS systems that generate alerts for sepsis, deterioration, or medication errors must have a documented process for capturing and reviewing false negatives — cases where the AI failed to alert on a real event. This is the highest-risk failure mode and the most scrutinised by regulators.

APA-3 (performance monitoring): CDS model performance must be monitored against clinical outcomes, not just against held-out test sets. Where outcome data is available (e.g. ICU mortality, 30-day readmission), it should inform ongoing model monitoring.

REL-2 (alert management): alert fatigue is a patient safety risk. CDS systems generating excessive false positive alerts must have a documented alert management and threshold review process.

4.3 Health Data Platforms and Population Health AI

BOM-3 (data minimisation): population health AI that uses longitudinal patient data must document the minimum dataset required for each analytical purpose and the review process for data that is no longer necessary.

BOM-1/REG-4 (retention): health data retention is governed by both clinical requirements (typically 10 years for adult records) and data protection law. AI training data that is no longer needed for model maintenance must be deleted on schedule.

BOM-3/REG-3 (third-party contracts): health data platforms that provide AI services to NHS, hospital, or payer clients must ensure that AI-specific obligations (data use limitations, model audit rights, incident notification) are included in platform agreements.

5. Certification Pathway for Healthcare Organisations

6. Frequently Asked Questions — Healthcare

Document Number	ODA3-2026-06-RPT-SCS-025	Version	1.0
Sector	Healthcare — Hospitals, Medical Devices, Diagnostics, Health Data Platforms	Classification	Public
Primary regulations	FDA SaMD Guidance (US); HIPAA (US); EU AI Act Annex III; EU MDR/IVDR; CDSCO AI/ML guidelines (India)	Companion documents	ODA3-2026-06-TCR-HAI-001; ODA3-2026-06-EXB-HAI-002

PURPOSE	This Sector Application Note (covering AI-IRF® v1.0 — 79 controls across 19 domains) translates AI-IRF® v1.0 controls into the language and obligations of healthcare regulators. It is a lead-generation and client-enablement document. It does not constitute regulatory or clinical advice. Healthcare organisations should consult qualified regulatory counsel before making compliance claims.

LICENCE NOTICE — GEL v1.0 | Public Document This document is part of the GAISSF Ecosystem published by ODA3 Institute (ODA3 Pvt Ltd) under the GAISSF Ecosystem Licence (GEL v1.0), effective 1 June 2026. GAISSF™, UAIF®, AI-IRF®, AI IRF CERT®, and ODA3® are registered trademarks of ODA3 Pvt Ltd (GEL §9.1). ODA3 Institute is the sole owner, proprietor, and governing body of the AI-IRF® framework and AI IRF CERT® scheme in perpetuity (GEL §10.5). Commercial Use of this document — including use in consulting, advisory, regulatory submissions prepared for fee, or training delivery — requires a separate written commercial licence from ODA3 Institute (GEL §3.4). AI training data use prohibited without licence (GEL §3.6). Disclaimer: provided “AS IS” without warranties (GEL §12). Governing law: Republic of India; DIAC arbitration, New Delhi seat (GEL §14). All enquiries: https://docs.oda3.org/ — Attribution (GEL §6): AI-IRF® v1.0 Sector Application Note — Healthcare © ODA3 Institute, GEL v1.0.

AI-IRF® v1.0 Domain	Regulatory obligation(s)	How AI IRF CERT® certification supports compliance
Model Lifecycle Security & Severity (MLC-1–5, APA-3, SEV-CLS/RPT)	FDA GMLP (model development/testing/monitoring); EU AI Act Art. 15 (accuracy, robustness); EU MDR Annex I (GSPR for software)	Verifies model validation, performance monitoring, and drift detection — provides documentation for FDA pre-market submissions, PCCP performance thresholds, and EU AI Act Art. 15 accuracy/robustness requirements
AI Supply Chain & BOM (BOM-1–5, REG-4)	FDA GMLP (data quality); HIPAA minimum necessary; EU AI Act Art. 10 (data governance); CDSCO population validation	Audit covers training data quality, bias assessment against demographic groups (critical for CDSCO and FDA), lineage, and minimisation — addresses HIPAA minimum necessary standard and EU AI Act data governance documentation
Regulatory Compliance & Transparency (REG-1–4)	EU AI Act Art. 13 (transparency to deployers); FDA guidance on explainability for clinical decision support; CDSCO documentation requirements	Certification demonstrates that clinical AI outputs are explainable to the required degree for the risk tier — supports clinical adoption, clinician oversight obligations, and regulatory documentation
Agentic Permissions (APA-1–5, REL-2–3)	EU AI Act Art. 14 (human oversight); FDA SaMD intended use (clinician in the loop for high-risk decisions); CDSCO draft guidance	Verifies that clinician oversight mechanisms, override capabilities, and alert management are implemented — critical for SaMD that informs but does not replace clinical judgment
Regulatory Compliance & Severity (REG-1–4, SEV-CLS/RPT)	EU AI Act Art. 9 (risk management system); FDA TPLC approach; HIPAA breach notification (SEV-RPT/MSR-3); CDSCO post-market surveillance	Board-level AI governance, incident response, and post-market monitoring procedures are verified — maps to FDA TPLC post-market surveillance obligations and EU AI Act risk management system requirements
Physical AI Safety & Zero Trust (PHY-1–4, ZTA-3–4)	EU MDR Art. 83 (post-market surveillance); FDA post-market performance monitoring; hospital BCP for clinical AI systems	Covers AI system continuity and recovery — ensures clinical workflows dependent on AI systems have tested backup procedures, addressing hospital accreditation and regulatory continuity expectations
Zero Trust AI Architecture & Model Extraction Defense (ZTA-1–4, MEX-1–2)	HIPAA Security Rule (access controls, audit logs, transmission security); EU MDR Annex I GSPR (IT security); FDA cybersecurity guidance for medical devices	Security controls for AI systems handling PHI — maps directly to HIPAA Security Rule technical safeguards and FDA cybersecurity guidance for networked medical devices
AI Supply Chain & BOM (BOM-3–5)	HIPAA BAA requirements; EU AI Act Art. 25 (obligations of deployers using third-party AI); FDA oversight of AI sub-components	Verifies that third-party AI model providers are assessed, contracted, and monitored — addresses HIPAA BAA obligations and EU AI Act deployer responsibilities for third-party AI components

Step	Activity	Healthcare context
1	Scope definition	Identify the AI systems in scope. Prioritise AI systems that meet FDA SaMD or EU MDR AI definitions, or that process PHI. Clinical decision support AI with direct patient safety implications should be certified before administrative AI.
2	Regulatory mapping	Map your AI systems' regulatory obligations (FDA, EU AI Act, HIPAA, CDSCO) to AI-IRF® v1.0 controls using the mapping table in Section 3. Identify controls where you have existing regulatory documentation that can serve as audit evidence.
3	Readiness assessment	Complete the AI-IRF® v1.0 Readiness Assessment. Healthcare organisations typically find strong clinical validation documentation but weaker bias assessment, third-party supplier contracts, and post-market AI monitoring procedures.
4	Stage 1 audit	Document review. For medical device AI, the CB will cross-reference AI-IRF® v1.0 documentation with existing FDA 510(k)/De Novo submissions or EU MDR technical files — this reduces duplication.
5	Stage 2 audit	On-site or remote assessment. Involve clinical informatics and biomedical engineering teams alongside IT and legal. Audit days: 2–3 for a single AI system; 4–6 for a portfolio.
6	Certificate use	Use the AI IRF CERT® certificate in FDA pre-market submissions as governance evidence; in EU AI Act conformity assessment files; in hospital accreditation submissions (Joint Commission, NABH); and in client procurement responses.

Question	Answer
Is AI IRF CERT® a regulatory clearance for SaMD?	No. AI IRF CERT® is a governance certification — it demonstrates that your AI governance processes meet the AI-IRF® v1.0 standard. FDA 510(k)/De Novo clearance or EU MDR CE marking for SaMD requires separate regulatory submissions. AI IRF CERT® provides supporting evidence for those submissions but does not substitute for them.
Does certification cover HIPAA compliance?	AI IRF CERT® addresses the AI-specific dimensions of HIPAA (access controls, data minimisation, third-party BAAs, incident response) but does not replace a full HIPAA compliance programme. Many organisations hold both.
Can a hospital certify its internally developed clinical AI?	Yes. AI-IRF® v1.0 applies to any organisation that develops, deploys, or procures AI systems — including hospitals running internally developed predictive models for sepsis, deterioration, or patient flow.
How does this interact with ISO 13485 (quality management for medical devices)?	AI-IRF® v1.0 is complementary to ISO 13485. ISO 13485 covers the quality management system for device development and manufacture. AI-IRF® v1.0 addresses AI-specific governance, model risk, and ongoing performance management — elements ISO 13485 does not specifically require.

Authoritative source

Download the approved DOCX source →

This accessible HTML rendering preserves the publication text for search and discovery. The approved source file governs where formatting differs.